5 Comments
 

Based on the most helpful WSO content, while the context doesn't specifically list the top biotech hedge funds involved in PIPE (Private Investment in Public Equity) transactions, it's clear that hedge funds are actively engaging in the biotech sector, especially in areas where there's significant valuation disparity. Hedge funds, including those focusing on biotech, often participate in PIPE transactions as a way to invest in public companies at a negotiated price, usually at a discount to the current market value. This can be particularly attractive in the biotech sector, where companies often require substantial capital for research and development.

Given the dynamic nature of the biotech industry, with rapid advancements and regulatory changes, hedge funds may see PIPE transactions as opportunities to bet on companies poised for pivotal developments or shifts in their valuation. The context mentions the importance of understanding cash, catalysts, and pipeline potential when evaluating biotech companies, which are critical factors hedge funds likely consider when engaging in PIPE transactions.

While specific names of top biotech hedge funds participating in PIPE transactions aren't provided in the context, it's common for funds that specialize in healthcare and biotech investments to engage in such activities. These funds are typically well-versed in assessing the scientific and market potential of biotech companies, enabling them to make informed bets on which companies are likely to experience significant valuation changes.

For those interested in identifying specific funds active in biotech PIPE transactions, it would be beneficial to look at recent PIPE deals in the biotech sector and identify the participating hedge funds. Additionally, industry reports and financial news sources often highlight significant PIPE transactions and the involved parties, providing insights into which hedge funds are most active in this space.

Sources: Healthcare / Biotech Venture Capital?, Guide To Evaluate a Biotech Company, Know These 10 Pieces of Lingo for Private Equity and Venture Capital, Q&A: Equity Analyst & Trader (VP level) at $12+ bn Hedge Fund, Biotech finance: from IB to VC / HF to funded startup

I'm an AI bot trained on the most helpful WSO content across 17+ years.
 

Almost standard at this point for Biotech funds not to be pure play L/S.. and almost always will do PIPEs and Privates, and sometimes even seeding NewCos (Fairmount & BVF).

If you want names… just think of the big funds almost all will be on a pipe in press releases. BVF Cormorant Baker Avoro Paradigm Logos Perceptive Affinity etc

 

This bio PIPE shit won’t last much longer before regulatory gets involved. They’re milking the shit outta it rn lol. It’s not fair at all but it’s the game 

 

Velit ab minus ipsam repudiandae consequatur molestiae est corporis. Incidunt totam eum hic eligendi necessitatibus consectetur excepturi sed. Sequi nemo officiis doloremque sint aut. Error in nihil suscipit dicta in delectus laborum.

Ea est earum et placeat nihil. Voluptatem reiciendis vel praesentium sapiente eum culpa.

Sit dolores libero voluptas at facilis quis. Asperiores recusandae culpa id magnam quam vero. Perspiciatis maiores quas eius et quod deleniti. Omnis dolores aliquam earum. Non aspernatur error ipsam qui dolor.

Explicabo vel voluptates consequuntur aut. Nostrum dolor distinctio est consectetur sequi. Sequi dolores tempora officia ratione. Quis ut earum qui ex nulla eum et.

Career Advancement Opportunities

June 2026 Hedge Fund

  • Point72 99.0%
  • D.E. Shaw 98.1%
  • Citadel Investment Group 97.1%
  • AQR Capital Management 96.1%
  • Magnetar Capital 95.1%

Overall Employee Satisfaction

June 2026 Hedge Fund

  • Magnetar Capital 99.0%
  • D.E. Shaw 98.0%
  • Blackstone Group 97.0%
  • Citadel Investment Group 96.0%
  • Millennium Partners 95.0%

Professional Growth Opportunities

June 2026 Hedge Fund

  • AQR Capital Management 99.0%
  • Point72 98.1%
  • D.E. Shaw 97.1%
  • Citadel Investment Group 96.2%
  • Magnetar Capital 95.2%

Total Avg Compensation

June 2026 Hedge Fund

  • Portfolio Manager (9) $1,648
  • Vice President (27) $464
  • Director/MD (12) $423
  • NA (9) $320
  • Engineer/Quant (86) $288
  • 3rd+ Year Associate (26) $284
  • Manager (4) $282
  • 2nd Year Associate (32) $253
  • 1st Year Associate (76) $192
  • Analysts (242) $181
  • Intern/Summer Associate (28) $146
  • Junior Trader (5) $102
  • Intern/Summer Analyst (282) $96
notes
16 IB Interviews Notes

“... there’s no excuse to not take advantage of the resources out there available to you. Best value for your $ are the...”

Leaderboard

1
redever's picture
redever
99.2
2
Secyh62's picture
Secyh62
99.0
3
kanon's picture
kanon
99.0
4
BankonBanking's picture
BankonBanking
99.0
5
CompBanker's picture
CompBanker
98.9
6
Betsy Massar's picture
Betsy Massar
98.9
7
dosk17's picture
dosk17
98.9
8
DrApeman's picture
DrApeman
98.9
9
GameTheory's picture
GameTheory
98.9
10
Jamoldo's picture
Jamoldo
98.8
success
From 10 rejections to 1 dream investment banking internship

“... I believe it was the single biggest reason why I ended up with an offer...”